| | ||||
 |
|
|||
 >4x |
Module 263 -- Chemotaxis (chemokines) |
| General Properties | |
|---|---|
| Below we list the number of gene sets from which the module was composed was originally composed, and the number of genes and experiments that it contains. Clicking on the number of genes will display a detailed list of all the genes in the module. Clicking on the number of experiments will display a detailed list of all the experiments in the module. | |
| Num gene sets: | 4 |
| Num genes: | 45 (see 2684 additional genes for this module) |
| Num experiments: | 710 (267 induced, 443 repressed) |
| Parent module: | None |
| Children modules: | 108 |
| Gene sets | |
|---|---|
| Below we list the gene sets from which the module was originally composed. Clicking on a gene set will display all the genes associated with that gene set. Also listed are all the other modules in which the gene set participates. | |
| taxis | |
| energy taxis | |
| chemotaxis | |
| chemokine receptor binding | |
| Enriched clinical annotations | |||||||
|---|---|---|---|---|---|---|---|
| For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched. | |||||||
| Clinical annotation | Category | P-value | Hits | Hits(%) | Module hits in category | Arrays in annotation | Arrays |
| Lung tissue, cancer or cell line (Lung cancer*) | Lung cancer* | 5.4e-28 | 139 | 31.3 | 443 | 276 | 1945 |
| Cancer and cell line (Lung cancer*) | Lung cancer* | 1.2e-26 | 129 | 29.1 | 443 | 252 | 1945 |
| Cancer (Lung cancer*) | Lung cancer* | 1.2e-26 | 129 | 29.1 | 443 | 252 | 1945 |
| Lung cancer (Lung cancer*) | Lung cancer* | 1.8e-26 | 124 | 27.9 | 443 | 238 | 1945 |
| Lung cancer or cell line (Lung cancer*) | Lung cancer* | 1.8e-26 | 124 | 27.9 | 443 | 238 | 1945 |
| Non-tumor liver tissue (Liver cancer) | Liver cancer | 1.9e-21 | 58 | 79.4 | 73 | 76 | 207 |
| Non small cell lung cancer and cell line (Lung cancer*) | Lung cancer* | 1.0e-20 | 104 | 23.4 | 443 | 205 | 1945 |
| Non small cell lung cancer (Lung cancer*) | Lung cancer* | 1.0e-20 | 104 | 23.4 | 443 | 205 | 1945 |
| Liver tissue (Liver cancer*) | Liver cancer* | 2.5e-20 | 73 | 27.4 | 266 | 187 | 1945 |
| Liver tissue, cancer or cell line (Liver cancer*) | Liver cancer* | 9.4e-19 | 73 | 27.4 | 266 | 197 | 1945 |
| Cancer and cell line (Liver cancer) | Liver cancer | 4.6e-16 | 62 | 98.4 | 63 | 126 | 207 |
| Hepatitis infected liver (Liver cancer*) | Liver cancer* | 3.2e-14 | 57 | 21.4 | 266 | 156 | 1945 |
| Hematologic samples (Stimulated PBMC*) | Stimulated PBMC* | 4.3e-11 | 51 | 19.1 | 266 | 152 | 1945 |
| Lymphocytes (Stimulated PBMC*) | Stimulated PBMC* | 4.3e-11 | 51 | 19.1 | 266 | 152 | 1945 |
| Primary blood mononuclear cells (Stimulated PBMC*) | Stimulated PBMC* | 4.3e-11 | 51 | 19.1 | 266 | 152 | 1945 |
| Acute lymphocytic leukemia (Leukemia) | Leukemia | 1.3e-09 | 46 | 97.8 | 47 | 99 | 149 |
| Lymphocytes (Leukemia) | Leukemia | 4.6e-09 | 41 | 97.6 | 42 | 91 | 141 |
| Hematologic samples and cell lines (Stimulated PBMC*) | Stimulated PBMC* | 1.9e-08 | 52 | 19.5 | 266 | 182 | 1945 |
| Monocytes (Stimulated PBMC*) | Stimulated PBMC* | 1.9e-08 | 52 | 19.5 | 266 | 182 | 1945 |
| Stimulated immune cells (Stimulated PBMC*) | Stimulated PBMC* | 2.6e-08 | 44 | 16.5 | 266 | 143 | 1945 |
| Activated B like DLBCL (B lymphoma) | B lymphoma | 8.5e-08 | 15 | 46.8 | 32 | 30 | 245 |
| Cancer (Liver cancer) | Liver cancer | 1.1e-07 | 52 | 82.5 | 63 | 115 | 207 |
| B cells (Leukemia) | Leukemia | 5.1e-07 | 32 | 76.1 | 42 | 62 | 141 |
| Cell line (Breast cancer) | Breast cancer | 1.4e-06 | 16 | 55.1 | 29 | 30 | 152 |
| Diffuse large B cell lymphoma - DLBCL (B lymphoma) | B lymphoma | 5.6e-06 | 28 | 87.5 | 32 | 126 | 245 |
| Hepatocellular carcinoma (Liver cancer) | Liver cancer | 1.1e-05 | 46 | 73.0 | 63 | 104 | 207 |
| Breast cancer cell line (Breast cancer) | Breast cancer | 1.1e-05 | 11 | 37.9 | 29 | 17 | 152 |
| Bone marrow (Leukemia) | Leukemia | 1.7e-05 | 16 | 38.0 | 42 | 23 | 141 |
| Female hormonal cancer cell line (Breast cancer) | Breast cancer | 2.3e-05 | 10 | 34.4 | 29 | 15 | 152 |
| Diffuse large B cell lymphoma tumor or cell line (B lymphoma) | B lymphoma | 3.0e-05 | 28 | 87.5 | 32 | 134 | 245 |
| Cell line (Liver cancer) | Liver cancer | 3.3e-05 | 10 | 15.8 | 63 | 11 | 207 |
| Adenocarcinoma (Liver cancer) | Liver cancer | 3.8e-05 | 43 | 68.2 | 63 | 97 | 207 |
| Hematologic cancer and cell line (Stimulated PBMC) | Stimulated PBMC | 8.2e-05 | 15 | 39.4 | 38 | 30 | 182 |
| Macrophages (Stimulated PBMC) | Stimulated PBMC | 8.2e-05 | 15 | 39.4 | 38 | 30 | 182 |
| Live bacteria stimulated immune cells (Stimulated PBMC) | Stimulated PBMC | 9.6e-05 | 5 | 20 | 25 | 5 | 148 |
| Liver cancer cell line (Liver cancer) | Liver cancer | 0.0001 | 9 | 14.2 | 63 | 10 | 207 |
| Hematologic cancer and cell line (Stimulated immune*) | Stimulated immune* | 0.0001 | 18 | 6.7 | 266 | 53 | 1945 |
| Hematologic samples and cell lines (Stimulated immune*) | Stimulated immune* | 0.0001 | 18 | 6.7 | 266 | 53 | 1945 |
| Macrophages (Stimulated immune*) | Stimulated immune* | 0.0001 | 18 | 6.7 | 266 | 53 | 1945 |
| Monocytes (Stimulated immune*) | Stimulated immune* | 0.0001 | 18 | 6.7 | 266 | 53 | 1945 |
| Enriched GO annotations | ||||||
|---|---|---|---|---|---|---|
| For each GO annotation, we tested whether it was enriched in the set of genes of the module. Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of the module's genes in which they appear. We also show the fraction of the module's genes with the given GO annotation that are included in this module ('Hits (%)' column). For completeness, we also list the total number of genes in the module ('Module genes' column), total number of genes in the compendium in which the corresponding annotation is present ('Genes in annotation' column), and the total number of genes in the compendium ('Genes' column). | ||||||
| GO annotation | P-value | Hits | Hits(%) | Module genes | Genes in annotation | Genes |
| chemotaxis | 2.6e-85 | 44 | 97.7 | 45 | 73 | 4566 |
| energy taxis | 6.5e-85 | 44 | 97.7 | 45 | 74 | 4566 |
| taxis | 3.7e-84 | 44 | 97.7 | 45 | 76 | 4566 |
| chemokine receptor binding | 1.0e-67 | 32 | 71.1 | 45 | 35 | 4566 |
| inflammatory response | 7.5e-51 | 35 | 77.7 | 45 | 108 | 4566 |
| thermoregulation | 4.6e-49 | 34 | 75.5 | 45 | 105 | 4566 |
| receptor binding | 8.9e-36 | 34 | 75.5 | 45 | 235 | 4566 |
| response to biotic stimulus | 1.9e-32 | 41 | 91.1 | 45 | 600 | 4566 |
| response to stress | 1.9e-27 | 41 | 91.1 | 45 | 792 | 4566 |
| immune response | 9.5e-27 | 35 | 77.7 | 45 | 469 | 4566 |
| cell-cell signaling | 1.3e-26 | 27 | 60 | 45 | 194 | 4566 |
| signal transducer activity | 4.0e-26 | 43 | 95.5 | 45 | 1026 | 4566 |
| secretion | 5.0e-24 | 27 | 60 | 45 | 240 | 4566 |
| calcium ion homeostasis | 9.6e-20 | 11 | 24.4 | 45 | 16 | 4566 |
| metal ion homeostasis | 1.0e-15 | 11 | 24.4 | 45 | 30 | 4566 |
| cation homeostasis | 1.6e-15 | 11 | 24.4 | 45 | 31 | 4566 |
| cell ion homeostasis | 3.7e-15 | 11 | 24.4 | 45 | 33 | 4566 |
| signal transduction | 8.1e-15 | 32 | 71.1 | 45 | 831 | 4566 |
| conjugation without cellular fusion | 1.5e-14 | 17 | 37.7 | 45 | 152 | 4566 |
| G-protein coupled receptor protein signaling pathway | 2.5e-13 | 19 | 42.2 | 45 | 245 | 4566 |
| cell communication | 4.9e-13 | 33 | 73.3 | 45 | 1030 | 4566 |
| response to pest/pathogen/parasite | 8.8e-13 | 16 | 35.5 | 45 | 163 | 4566 |
| binding | 3.8e-12 | 33 | 73.3 | 45 | 1103 | 4566 |
| extracellular space | 3.9e-12 | 17 | 37.7 | 45 | 212 | 4566 |
| response to extracellular stimulus | 2.0e-11 | 23 | 51.1 | 45 | 500 | 4566 |
| peptide receptor activity | 4.0e-08 | 8 | 17.7 | 45 | 55 | 4566 |
| peptide receptor activity\, G-protein coupled | 6.1e-08 | 8 | 17.7 | 45 | 58 | 4566 |
| cytosolic calcium ion concentration elevation | 7.6e-08 | 6 | 13.3 | 45 | 24 | 4566 |
| G-protein signaling\, coupled to IP3 second messenger (phospholipase C activating) | 3.0e-07 | 7 | 15.5 | 45 | 48 | 4566 |
| response to viruses | 5.7e-07 | 5 | 11.1 | 45 | 18 | 4566 |
| humoral immune response | 1.5e-06 | 9 | 20 | 45 | 118 | 4566 |
| heparin binding | 1.9e-06 | 6 | 13.3 | 45 | 40 | 4566 |
| glycosaminoglycan binding | 3.4e-06 | 6 | 13.3 | 45 | 44 | 4566 |
| activation of MAPK | 3.8e-06 | 4 | 8.8 | 45 | 12 | 4566 |
| humoral defense mechanism (sensu Invertebrata) | 5.0e-06 | 7 | 15.5 | 45 | 72 | 4566 |
| cellular defense response | 7.4e-06 | 6 | 13.3 | 45 | 50 | 4566 |
| G-protein chemoattractant receptor activity | 7.6e-06 | 4 | 8.8 | 45 | 14 | 4566 |
| rhodopsin-like receptor activity | 9.5e-06 | 9 | 20 | 45 | 147 | 4566 |
| cell motility | 1.1e-05 | 8 | 17.7 | 45 | 113 | 4566 |
| G-protein coupled receptor activity | 3.1e-05 | 9 | 20 | 45 | 170 | 4566 |
| MAPKKK cascade (osmolarity sensing) | 4.3e-05 | 4 | 8.8 | 45 | 21 | 4566 |
| sensory perception | 5.0e-05 | 18 | 40 | 45 | 700 | 4566 |
| MAPKKK cascade | 8.9e-05 | 4 | 8.8 | 45 | 25 | 4566 |
| viral replication | 0.0001 | 3 | 6.6 | 45 | 10 | 4566 |
| two-component signal transduction system (phosphorelay) | 0.0001 | 4 | 8.8 | 45 | 26 | 4566 |
| Visual display | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Below is a visual display of the module. Shown are those arrays in which the module's genes significantly change, and the direction of change (induction/repression) in each array is indicated (middle, labeled 'Module changes'; red/green row). The arrays that correspond to the significant clinical attributes are also shown (top; brown rows). The gene sets that compose the module are also shown (left) along with an indication of the membership of the module genes in these gene sets. | |||||||||
| You can also view the images within GeneXPress by loading the module gxp file file. | |||||||||
| Note: Since there are 710 experiments, this image does not display the individual experiment names, but rather condenses each experiment to a single pixel without displaying its name. You can fully view the image for this module within GeneXPress, by loading any of the four files mentioned in the line above | |||||||||
|
|||||||||
